Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01821443 : A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Pathologically (histologically or cytologically) proven diagnosis of a
non-hematopoietic malignancy other than small cell lung cancer and germ cell
malignancy within 5 years of registration. If the original histologic proof of
malignancy is greater than 5 years, then pathological confirmation is required (e.g.
from extra- or intracranial disease).

- Patients with 1-10 measurable brain metastases on a diagnostic-quality
contrast-enhanced magnetic resonance imaging (MRI) scan obtained within 30 days prior
to registration.

- Patients with ?10 cc largest tumor volume, and ?15 cc total tumor volume.

- History/physical examination within 30 days prior to registration.

- If an open biopsy is performed, the patient must be at least one week post biopsy.
This requirement does not apply to patients who undergo stereotactic biopsies.

- Age ?18 years.

- Karnofsky performance status ?70 (RTOG recursive partitioning analysis (RPA) Class I &

- Minimum pre-treatment oNCF score ?70.

- Patients must provide study-specific informed consent prior to study entry.

- Women of child-bearing age must have a negative, quantitative serum pregnancy test ?14
days prior to study entry, or have a documented reason why such a test is not
necessary (e.g. history of tubal ligation).

- Patients must be able to speak and read English fluently (required for the use of
online NCF testing).

Exclusion Criteria:

- Clinical (e.g. multiple cranial nerve deficits in the absence of obvious radiographic
disease to explain symptoms) or radiographic evidence of leptomeningeal disease.

- Patients with measurable brain metastasis(es) resulting from small cell lung cancer
and/or germ cell malignancy

- No documentation of prior cytotoxic or other therapy for malignancy if such therapy
was previously received. Note: This does not apply to patients with synchronous
metastases at initial diagnosis.

- Contraindication to MR imaging, such as implanted metal devices or foreign bodies,
severe claustrophobia, or contraindications to contrast agent administration.

- Estimated glomerular filtration rate (eGFR) <60 within 6 weeks prior to registration.

- Prior radiation therapy to the brain.

- Severe, active co-morbidity, defined as follows:

- Unstable angina, and/or congestive heart failure requiring hospitalization within
the last 6 months.

- Transmural myocardial infarction within the last 6 months.

- Acute bacterial or fungal infection requiring intravenous antibiotics at the time
of registration.

- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.

- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization, or precluding study therapy at the time of

- Uncontrolled, clinically significant cardiac arrhythmias.

- Radiologic or clinical evidence of hydrocephalus, or history of previously
treated hydrocephalus.

- Women of childbearing potential and male participants who are sexually active and not
willing/able to use medically acceptable forms of contraception; this exclusion is
necessary because the radiation treatment involved in this study is potentially
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557